World Orphan Drug Congress
Meet with us at World Orphan Drug Congress!
At the World Orphan Drug Congress USA, leaders across biotech, pharma, and regulatory agencies come together to explore the evolving rare disease landscape—from advanced therapies and innovative trial design to regulatory strategy and patient-centric development approaches.
Join Our Rare Disease Experts in These Sessions:
Advanced Therapies Track
- Date: 10 June | 11:25 am-3:30 pm EDT
- Chair: Adam Bloomfield, MD, FAAP
Continuity by Design: A Site- and Patient-Centric Approach to Trial Consolidation
- Date: 11 June 2026 | 12:00–12:20 pm EDT
- Moderator: Angi Robinson, Senior Vice President, Specialty Areas
- Panel featuring Jackie Brown, Vice President, Project Delivery, Premier Research, and Arthur Van Leerberghe, Executive Director, Development Business Operations and Site Head (Basel, Switzerland), Mirum Pharmaceuticals
This discussion explores how four ongoing studies across two indications were consolidated into a single, unified trial. Developed in close collaboration with regulators, the approach focuses on maintaining continuity of care through a site- and patient-centric model—while improving governance, streamlining operations, and preserving patient access through to commercial launch.
On-Site
- Angi Robinson, Sr. VP, Specialty Areas
- Andreas Schreiner, Sr. VP, Medical Affairs
- Ken Ndugga-Kabuye, VP, Cell and Gene Therapy
- Adam Bloomfield, VP, Medical Affairs
- Jackie Brown, VP, Project Delivery
- Seth DePuy, Regulatory Affairs Director
- Matt Garon, Sr. Director, Business Development
- Nathan Anderson, Director, Business Development
Meet with our team to discuss rare disease and advanced therapy strategies—from trial design and consolidation to regulatory and operational execution.
Request a meeting with us at World Orphan Drug Congress
By submitting your information to us through this webform, your business details will be added to our database. In accordance with our Privacy Notice, we may then contact you with marketing information about Premier Research that might be of interest to you. We will never sell your details to third parties. You can unsubscribe from marketing communications at any time.